What is Precision BioSciences' operating income?

Precision BioSciences' total operating income in 2025 was -$52.15 million, based on the following breakdown: Total Gross Profit: $34.26 million Total Operating Expenses: $86.87 million

Precision BioSciences (DTIL) Financials

$6.72 +0.29 (+4.51%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.71 -0.01 (-0.15%)

As of 10/9/2026 07:30 PM Eastern

Compare

Annual Income Statements for Precision BioSciences

This table shows Precision BioSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-93	-109	-31	-112	-61	7.17	-46
Consolidated Net Income / (Loss)	-99	-108	-31	-112	-61	7.17	-46
Net Income / (Loss) Continuing Operations	-99	-108	-31	-73	-43	7.17	-47
Total Pre-Tax Income	-93	-109	-31	-73	-43	7.17	-46
Total Operating Income	-87	-110	-39	-62	-44	-26	-52
Total Gross Profit	22	24	116	25	49	69	34
Total Revenue	22	24	116	25	49	69	34
Operating Revenue	22	24	116	25	49	69	34
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	109	134	155	98	92	95	87
Selling, General & Admin Expense	27	36	40	41	39	35	32
Research & Development Expense	82	98	115	46	53	60	54
Impairment Charge	-	-	0.00	11	0.00	0.00	0.04
Other Special Charges / (Income)	-	-	0.03	0.03	-	-	0.42
Total Other Income / (Expense), net	-5.67	0.82	8.80	0.27	1.21	33	6.00
Interest Expense	0.18	0.00	0.13	1.11	2.23	1.78	1.42
Interest & Investment Income	4.27	0.82	6.38	1.89	2.76	5.68	-1.05
Other Income / (Expense), net	-9.76	0.00	2.56	-0.51	0.68	29	8.46
Net Income / (Loss) Discontinued Operations	-	-	-	-39	-19	0.00	0.89
Basic Earnings per Share	($2.21)	($2.09)	($0.52)	($38.10)	($15.96)	$1.05	($3.56)
Weighted Average Basic Shares Outstanding	41.99M	52.03M	58.69M	2.93M	3.84M	6.83M	12.83M
Diluted Earnings per Share	($2.21)	($2.09)	($0.52)	($38.10)	($15.96)	$1.04	($3.56)
Weighted Average Diluted Shares Outstanding	41.99M	52.03M	58.69M	2.93M	3.84M	6.88M	12.83M
Weighted Average Basic & Diluted Shares Outstanding	41.99M	52.03M	58.69M	111.30M	6.92M	10.48M	24.73M

This table shows Precision BioSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-16	8.59	33	-16	-18	-21	-24	-22	20	-18	-33
Consolidated Net Income / (Loss)	-16	8.59	33	-16	-18	-21	-24	-22	20	-18	-33
Net Income / (Loss) Continuing Operations	-13	8.59	33	-16	-18	-21	-23	-22	19	-18	-33
Total Pre-Tax Income	-13	8.59	33	-16	-18	-21	-23	-22	20	-18	-33
Total Operating Income	-15	-4.19	24	-21	-25	-22	-22	-21	13	-9.08	-19
Total Gross Profit	7.04	18	50	0.58	0.64	0.03	0.02	0.01	34	11	0.00
Total Revenue	7.04	18	50	0.58	0.64	0.03	0.02	0.01	34	11	0.00
Operating Revenue	7.04	18	50	0.58	0.64	0.03	0.02	0.01	34	11	0.00
Total Cost of Revenue	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00	0.00
Total Operating Expenses	22	22	26	22	25	22	22	21	22	20	19
Selling, General & Admin Expense	8.54	8.43	8.53	8.77	9.58	8.55	9.13	7.33	7.23	6.80	6.77
Research & Development Expense	13	13	17	13	16	14	13	13	14	13	12
Other Special Charges / (Income)	-	-	0.19	0.00	-	0.01	0.03	-0.00	-	-0.00	-0.00
Total Other Income / (Expense), net	1.45	13	8.79	4.85	6.91	1.56	-1.62	-1.11	7.18	-9.37	-13
Interest Expense	0.58	0.57	0.56	0.26	0.39	0.35	0.36	0.36	0.35	0.31	0.30
Interest & Investment Income	0.96	3.38	0.89	0.89	0.52	2.67	0.45	0.44	-4.60	1.00	0.94
Other Income / (Expense), net	1.07	9.97	8.46	4.22	6.78	-0.76	-1.71	-1.18	12	-10	-14
Basic Earnings per Share	($4.24)	$1.70	$4.70	($2.25)	($2.60)	($2.21)	($2.13)	($1.84)	$1.57	($0.75)	($1.26)
Weighted Average Basic Shares Outstanding	3.84M	5.06M	6.97M	7.29M	6.83M	9.29M	11.05M	11.82M	12.83M	24.63M	25.86M
Diluted Earnings per Share	($4.24)	$1.70	$4.67	($2.25)	($2.60)	($2.21)	($2.13)	($1.84)	$1.57	($0.75)	($1.26)
Weighted Average Diluted Shares Outstanding	3.84M	5.06M	7.01M	7.29M	6.88M	9.29M	11.05M	11.82M	12.83M	24.63M	25.86M
Weighted Average Basic & Diluted Shares Outstanding	6.92M	6.93M	7.23M	7.67M	10.48M	11.09M	11.79M	13.26M	24.73M	25.80M	27.60M

This table details how cash moves in and out of Precision BioSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	78	-91	54	46	-73	-8.21	29
Net Cash From Operating Activities	-71	-87	-11	-46	-84	-58	-66
Net Cash From Continuing Operating Activities	-71	-87	-31	-46	-85	-58	-66
Net Income / (Loss) Continuing Operations	-93	-109	-31	-112	-61	7.17	-46
Consolidated Net Income / (Loss)	-93	-109	-31	-112	-61	7.17	-46
Depreciation Expense	5.32	8.78	8.98	7.80	6.82	3.40	1.47
Amortization Expense	0.00	1.04	1.26	1.15	1.29	0.73	0.79
Non-Cash Adjustments To Reconcile Net Income	18	14	-22	31	9.94	-5.47	3.54
Changes in Operating Assets and Liabilities, net	-1.34	-2.01	12	26	-41	-64	-26
Net Cash From Investing Activities	-25	-5.03	-5.80	-3.32	5.83	-0.22	-0.63
Net Cash From Continuing Investing Activities	-25	-5.03	-5.80	-3.32	5.83	-0.22	-0.63
Purchase of Property, Plant & Equipment	-25	-5.03	-5.05	-3.32	-1.96	-0.25	-0.09
Sale of Property, Plant & Equipment	-	-	-	0.00	0.11	0.06	0.07
Other Investing Activities, net	-	0.00	-0.75	0.00	-0.32	-0.03	-0.62
Net Cash From Financing Activities	173	1.33	71	95	5.39	50	95
Net Cash From Continuing Financing Activities	173	1.33	71	95	5.39	50	95
Repayment of Debt	-	0.00	-2.51	0.00	0.00	-23	0.00
Issuance of Debt	40	0.00	4.97	20	0.00	22	0.00
Issuance of Common Equity	135	0.00	60	74	4.99	50	95
Other Financing Activities, net	1.26	1.33	7.59	0.84	0.40	0.25	0.22
Cash Interest Paid	-	-	0.07	0.82	2.02	1.74	1.36

This table details how cash moves in and out of Precision BioSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	-5.55	21	-14	-2.24	-13	-8.68	-15	-14	66	-11	-13
Net Cash From Operating Activities	-8.42	-19	-15	-5.91	-19	-19	-20	-15	-11	-12	-13
Net Cash From Continuing Operating Activities	-9.06	-19	-15	-5.91	-19	-19	-20	-15	-12	-12	-13
Net Income / (Loss) Continuing Operations	-16	8.59	33	-16	-18	-21	-24	-22	20	-18	-33
Consolidated Net Income / (Loss)	-16	8.59	33	-16	-18	-21	-24	-22	20	-18	-33
Depreciation Expense	1.28	1.14	1.09	0.72	0.45	0.40	0.38	0.35	0.35	0.30	0.25
Amortization Expense	0.13	0.40	0.15	0.04	0.14	0.17	0.15	0.11	0.36	0.46	0.35
Non-Cash Adjustments To Reconcile Net Income	2.86	-0.02	3.64	14	-23	4.18	6.40	2.98	-8.90	12	16
Changes in Operating Assets and Liabilities, net	2.96	-29	-52	-4.11	21	-3.23	-3.69	3.06	-23	-5.86	2.55
Net Cash From Investing Activities	0.04	-0.03	-0.03	-0.06	-0.10	-0.31	-0.01	0.02	-0.33	-0.11	0.00
Net Cash From Continuing Investing Activities	0.04	-0.03	-0.03	-0.06	-0.10	-0.31	-0.01	0.02	-0.33	-0.11	0.00
Sale of Property, Plant & Equipment	0.04	0.06	-	-	-	0.00	0.01	0.02	0.04	0.00	0.00
Cash Interest Paid	0.53	0.53	0.53	0.31	0.37	0.34	0.35	0.35	0.33	0.30	0.30

This table presents Precision BioSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	139	235	150	211	238	160	136	154
Total Current Assets	116	194	106	162	199	136	95	119
Cash & Equivalents	103	181	90	144	190	117	86	111
Short-Term Investments	-	-	-	-	-	0.00	0.41	4.76
Accounts Receivable	0.52	0.97	10	0.49	0.72	0.90	0.23	0.00
Prepaid Expenses	8.91	9.50	5.76	17	6.03	5.98	6.44	3.11
Other Current Assets	3.05	2.32	0.00	0.17	1.23	0.91	2.01	0.05
Plant, Property, & Equipment, net	21	40	35	25	12	6.34	3.09	1.43
Total Noncurrent Assets	1.78	1.99	9.50	25	27	17	38	34
Long-Term Investments	-	-	-	6.84	4.75	3.21	3.21	0.74
Intangible Assets	1.47	1.43	1.37	2.05	0.73	0.40	0.62	1.17
Other Noncurrent Operating Assets	0.31	0.56	8.13	8.82	2.19	8.49	30	32
Total Liabilities & Shareholders' Equity	139	235	150	211	238	160	136	154
Total Liabilities	99	97	106	120	178	141	80	62
Total Current Liabilities	14	27	43	36	60	50	15	8.91
Accounts Payable	2.22	2.04	0.79	1.14	0.65	2.97	1.31	0.30
Accrued Expenses	2.46	2.40	3.27	4.03	1.83	1.56	2.02	1.71
Current Employee Benefit Liabilities	0.97	4.43	5.75	6.77	5.10	4.98	5.18	4.75
Other Current Liabilities	-	1.58	2.79	2.80	2.42	3.52	2.31	2.16
Total Noncurrent Liabilities	85	70	63	84	118	91	65	53
Long-Term Debt	-	-	-	2.48	22	0.00	22	22
Other Noncurrent Operating Liabilities	-	0.00	8.98	15	11	18	19	31
Total Equity & Noncontrolling Interests	40	138	44	91	60	19	56	92
Total Preferred & Common Equity	40	138	44	91	60	19	56	92
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	40	138	44	91	60	19	56	92
Common Stock	126	316	331	409	490	509	540	621
Retained Earnings	-85	-177	-286	-317	-428	-490	-482	-528
Treasury Stock	-0.95	-0.95	-0.95	-0.95	-0.95	-0.95	-0.95	-0.95

This table presents Precision BioSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	164	185	166	153	124	109	94	144	126
Total Current Assets	146	161	144	111	82	70	52	109	92
Cash & Equivalents	122	138	124	99	77	62	45	99	86
Short-Term Investments	-	-	-	2.45	0.00	0.00	0.00	1.81	1.47
Accounts Receivable	3.51	0.39	0.21	0.19	0.00	0.00	0.00	4.00	0.00
Prepaid Expenses	8.08	9.25	5.67	7.11	4.59	7.45	5.86	3.50	4.00
Other Current Assets	0.35	1.87	2.34	2.02	0.29	0.57	0.97	0.01	0.01
Plant, Property, & Equipment, net	8.74	5.29	4.23	3.56	2.72	2.36	2.03	1.18	0.96
Total Noncurrent Assets	9.75	19	18	39	40	36	40	34	33
Long-Term Investments	1.81	3.21	3.21	3.21	3.21	0.74	0.74	0.74	0.74
Intangible Assets	0.98	0.39	0.38	0.39	0.61	0.61	0.99	1.13	1.09
Other Noncurrent Operating Assets	1.31	8.22	7.92	30	30	29	33	32	32
Total Liabilities & Shareholders' Equity	164	185	166	153	124	109	94	144	126
Total Liabilities	135	148	91	88	75	75	77	68	81
Total Current Liabilities	51	33	33	12	12	14	15	7.76	7.14
Accounts Payable	0.53	1.14	1.14	0.96	0.92	1.12	1.34	0.94	0.83
Accrued Expenses	1.47	0.66	1.87	3.29	1.31	0.99	1.30	3.26	1.75
Current Employee Benefit Liabilities	3.83	1.22	2.48	3.59	1.29	2.45	3.16	1.14	2.37
Other Current Liabilities	3.34	3.95	3.14	2.66	2.26	2.13	2.07	2.42	2.20
Total Noncurrent Liabilities	85	114	58	76	63	61	62	60	73
Long-Term Debt	0.00	-	-	22	22	22	22	22	22
Other Noncurrent Operating Liabilities	11	39	31	28	20	19	20	38	51
Total Equity & Noncontrolling Interests	29	37	75	65	49	34	17	76	45
Total Preferred & Common Equity	29	37	75	65	49	34	17	76	45
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	29	37	75	65	49	34	17	76	45
Common Stock	503	519	524	531	553	562	566	624	626
Retained Earnings	-473	-481	-448	-465	-503	-527	-548	-547	-579
Treasury Stock	-0.95	-0.95	-0.95	-0.95	-0.95	-0.95	-0.95	-0.95	-0.95

This table displays calculated financial ratios and metrics derived from Precision BioSciences' official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	50,787,317.00	52,480,469.00	60,767,307.00	110,958,955.00	118,935,191.00	7,671,059.00	13,256,751.00
DEI Adjusted Shares Outstanding	1,692,911.00	1,749,349.00	2,025,577.00	3,698,632.00	3,964,506.00	7,671,059.00	13,256,751.00
DEI Earnings Per Adjusted Shares Outstanding	-54.86	-62.31	-15.11	-30.18	-15.47	0.93	-3.45
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	9.21%	375.72%	-78.28%	94.15%	40.98%	-50.12%
EBITDA Growth	0.00%	-9.13%	73.43%	-102.70%	35.14%	121.18%	-659.76%
EBIT Growth	0.00%	-13.27%	66.47%	-70.60%	31.47%	107.60%	-1,435.93%
NOPAT Growth	0.00%	-25.94%	64.15%	-58.24%	29.81%	14.55%	-39.53%
Net Income Growth	0.00%	-9.78%	71.71%	-264.80%	45.07%	111.69%	-737.98%
EPS Growth	0.00%	5.43%	75.12%	-264.80%	45.07%	106.52%	-442.31%
Operating Cash Flow Growth	0.00%	-23.05%	87.58%	-321.57%	-83.84%	30.52%	-12.66%
Free Cash Flow Firm Growth	0.00%	0.00%	78.30%	223.86%	-476.15%	-23.70%	52.05%
Invested Capital Growth	0.00%	-6.58%	-25.31%	-111.73%	36.79%	87.38%	82.53%
Revenue Q/Q Growth	0.00%	0.00%	-2.12%	20.44%	-6.81%	-8.52%	4,808.88%
EBITDA Q/Q Growth	0.00%	-1,192.94%	-21.27%	42.14%	-203.47%	-40.62%	50.82%
EBIT Q/Q Growth	0.00%	0.00%	-14.59%	38.59%	-110.16%	-56.48%	49.43%
NOPAT Q/Q Growth	0.00%	0.00%	-22.54%	39.09%	-123.27%	-61.43%	41.74%
Net Income Q/Q Growth	0.00%	0.00%	1.36%	-5.83%	16.59%	-16.89%	45.31%
EPS Q/Q Growth	0.00%	0.00%	1.89%	-5.83%	16.59%	-11.86%	49.65%
Operating Cash Flow Q/Q Growth	0.00%	7.52%	-1,639.26%	3.86%	13.76%	-21.29%	10.14%
Free Cash Flow Firm Q/Q Growth	0.00%	-629.62%	-196.06%	197.62%	-45.92%	-30.11%	39.05%
Invested Capital Q/Q Growth	15.66%	-12.52%	0.92%	-10.87%	-7.23%	39.85%	70.69%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-412.11%	-411.84%	-23.01%	-214.65%	-71.71%	10.77%	-120.91%
Operating Margin	-392.14%	-452.25%	-34.08%	-248.26%	-89.76%	-38.08%	-152.19%
EBIT Margin	-436.02%	-452.25%	-31.87%	-250.29%	-88.35%	4.76%	-127.50%
Profit (Net Income) Margin	-443.16%	-445.48%	-26.49%	-444.80%	-125.84%	10.43%	-133.45%
Tax Burden Percent	106.11%	99.25%	100.09%	153.12%	144.19%	100.00%	99.07%
Interest Burden Percent	95.79%	99.25%	83.04%	116.06%	98.78%	219.17%	105.65%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-110.56%	-118.40%	-45.14%	-147.28%	-154.66%	19.05%	-61.52%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-51.87%	-57.00%	-20.36%	-27.94%	-21.64%	2.21%	-30.04%
Return on Assets (ROA)	-52.72%	-56.14%	-16.92%	-49.65%	-30.82%	4.84%	-31.45%
Return on Common Equity (ROCE)	-110.56%	-118.40%	-45.14%	-147.28%	-154.66%	19.05%	-61.52%
Return on Equity Simple (ROE_SIMPLE)	-71.25%	-243.52%	-33.57%	-184.73%	-325.11%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-61	-77	-28	-44	-31	-26	-37
NOPAT Margin	-274.50%	-316.57%	-23.86%	-173.78%	-62.83%	-38.08%	-106.54%
Net Nonoperating Expense Percent (NNEP)	-20.74%	-23.13%	-2.56%	-41.37%	-22.27%	41.41%	-11.53%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-74.18%	-33.24%	-31.84%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	121.53%	148.45%	34.34%	164.49%	80.22%	51.38%	94.09%
R&D to Revenue	370.61%	403.79%	99.75%	183.77%	109.54%	86.70%	158.10%
Operating Expenses to Revenue	492.14%	552.25%	134.11%	391.59%	189.76%	138.08%	253.53%
Earnings before Interest and Taxes (EBIT)	-97	-110	-37	-63	-43	3.27	-44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-92	-100	-27	-54	-35	7.40	-41
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.10	9.85	4.93	2.18	2.30	0.52	0.60
Price to Tangible Book Value (P/TBV)	5.15	10.17	5.05	2.21	2.35	0.52	0.61
Price to Revenue (P/Rev)	31.72	18.02	3.89	5.26	0.89	0.43	1.61
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	4.08	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	24.52%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	23.59	14.33	2.61	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.03	0.37	1.19	0.40	0.24
Long-Term Debt to Equity	0.00	0.00	0.03	0.37	0.00	0.40	0.24
Financial Leverage	-1.31	-1.48	-1.75	-2.17	-3.48	-2.14	-1.08
Leverage Ratio	2.10	2.11	2.67	2.97	5.02	3.94	1.96
Compound Leverage Factor	2.01	2.09	2.21	3.44	4.96	8.63	2.07
Debt to Total Capital	0.00%	0.00%	2.65%	26.89%	54.30%	28.36%	19.54%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	54.30%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	2.65%	26.89%	0.00%	28.36%	19.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	97.35%	73.11%	45.70%	71.64%	80.46%
Debt to EBITDA	0.00	0.00	-0.09	-0.41	-0.64	3.02	-0.54
Net Debt to EBITDA	0.00	0.00	5.57	3.19	2.79	-9.08	2.27
Long-Term Debt to EBITDA	0.00	0.00	-0.09	-0.41	0.00	3.02	-0.54
Debt to NOPAT	0.00	0.00	-0.09	-0.51	-0.73	-0.85	-0.61
Net Debt to NOPAT	0.00	0.00	5.37	3.95	3.18	2.57	2.57
Long-Term Debt to NOPAT	0.00	0.00	-0.09	-0.51	0.00	-0.85	-0.61
Altman Z-Score	2.90	-1.93	0.83	-2.13	-4.04	-3.45	-4.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	7.19	2.46	4.50	3.34	2.73	6.34	13.32
Quick Ratio	6.75	2.33	4.01	3.19	2.59	5.78	12.97
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-74	-16	20	-75	-93	-44
Operating Cash Flow to CapEx	-287.91%	-1,736.95%	-214.78%	-1,378.52%	-4,546.70%	-30,760.53%	-346,542.11%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-121.80	17.92	-33.59	-52.00	-31.24
Operating Cash Flow to Interest Expense	-390.19	0.00	-82.22	-41.18	-37.72	-32.80	-46.30
Operating Cash Flow Less CapEx to Interest Expense	-525.72	0.00	-120.50	-44.17	-38.55	-32.90	-46.32
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.12	0.13	0.64	0.11	0.24	0.46	0.24
Accounts Receivable Turnover	29.89	4.43	22.03	41.55	60.12	121.59	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.73	0.65	3.84	1.36	5.37	14.57	15.18
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	12.21	82.40	16.57	8.78	6.07	3.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	12.21	82.40	16.57	8.78	6.07	3.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	-43	-45	-57	-120	-76	-9.60	-1.68
Invested Capital Turnover	-0.52	-0.55	-2.26	-0.28	-0.50	-1.60	-6.08
Increase / (Decrease) in Invested Capital	0.00	-2.80	-11	-64	44	66	7.92
Enterprise Value (EV)	525	348	302	-40	-54	-38	-39
Market Capitalization	705	438	450	132	43	29	55
Book Value per Share	$2.72	$0.85	$1.50	$0.54	$0.16	$7.35	$6.96
Tangible Book Value per Share	$2.70	$0.82	$1.47	$0.54	$0.16	$7.27	$6.87
Total Capital	138	44	94	83	41	79	115
Total Debt	0.00	0.00	2.48	22	22	22	22
Total Long-Term Debt	0.00	0.00	2.48	22	0.00	22	22
Net Debt	-181	-90	-148	-172	-97	-67	-94
Capital Expenditures (CapEx)	25	5.03	5.05	3.32	1.85	0.19	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-27	-18	-50	-7.89	-6.30	-5.76
Debt-free Net Working Capital (DFNWC)	167	63	126	139	109	80	110
Net Working Capital (NWC)	167	63	126	139	86	80	110
Net Nonoperating Expense (NNE)	38	31	3.04	68	31	-33	9.22
Net Nonoperating Obligations (NNO)	-181	-90	-148	-181	-95	-66	-94
Total Depreciation and Amortization (D&A)	5.32	9.81	10	8.94	8.11	4.13	2.26
Debt-free, Cash-free Net Working Capital to Revenue	-63.61%	-111.44%	-15.48%	-199.76%	-16.20%	-9.18%	-16.80%
Debt-free Net Working Capital to Revenue	749.80%	258.33%	108.87%	555.59%	223.25%	116.47%	320.53%
Net Working Capital to Revenue	749.80%	258.33%	108.87%	555.59%	177.26%	116.47%	320.53%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($62.70)	($15.60)	($38.10)	($15.96)	$1.05	($3.56)
Adjusted Weighted Average Basic Shares Outstanding	0.00	1.90M	2.03M	2.93M	3.84M	6.83M	12.83M
Adjusted Diluted Earnings per Share	$0.00	($62.70)	($15.60)	($38.10)	($15.96)	$1.04	($3.56)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	1.90M	2.03M	2.93M	3.84M	6.88M	12.83M
Adjusted Basic & Diluted Earnings per Share	$0.00	($62.70)	($15.60)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	1.73M	1.96M	3.71M	6.92M	10.48M	24.73M
Normalized Net Operating Profit after Tax (NOPAT)	-61	-77	-28	-36	-31	-18	-36
Normalized NOPAT Margin	-274.50%	-316.57%	-23.84%	-143.45%	-62.83%	-26.66%	-105.60%
Pre Tax Income Margin	-417.65%	-448.86%	-26.47%	-290.50%	-87.28%	10.43%	-134.70%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	-532.76	0.00	-278.95	-56.54	-19.31	1.84	-30.72
NOPAT to Interest Expense	-335.40	0.00	-208.81	-39.26	-13.73	-14.68	-25.67
EBIT Less CapEx to Interest Expense	-668.29	0.00	-317.23	-59.53	-20.14	1.73	-30.73
NOPAT Less CapEx to Interest Expense	-470.93	0.00	-247.09	-42.25	-14.56	-14.79	-25.68
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Precision BioSciences' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	118,935,191.00	6,916,239.00	6,925,598.00	7,233,760.00	7,671,059.00	10,481,931.00	11,088,234.00	11,786,991.00	13,256,751.00	24,726,695.00	25,802,247.00
DEI Adjusted Shares Outstanding	3,964,506.00	6,916,239.00	6,925,598.00	7,233,760.00	7,671,059.00	10,481,931.00	11,088,234.00	11,786,991.00	13,256,751.00	24,726,695.00	25,802,247.00
DEI Earnings Per Adjusted Shares Outstanding	-4.11	1.24	4.73	-2.27	-2.31	-1.96	-2.12	-1.85	1.52	-0.75	-1.27
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-33.59%	100.27%	152.15%	-95.61%	-90.93%	-99.84%	-99.96%	-97.74%	5,261.13%	37,272.41%	-100.00%
EBITDA Growth	-212.68%	162.48%	4,820.92%	-61.57%	-40.78%	-404.44%	-168.11%	-31.22%	244.94%	17.61%	-41.81%
EBIT Growth	-258.00%	140.97%	1,166.57%	-41.53%	-30.71%	-495.21%	-172.34%	-28.09%	236.34%	16.33%	-41.16%
NOPAT Growth	-212.60%	55.21%	1,202.41%	-72.09%	-66.86%	-269.68%	-163.42%	2.86%	171.92%	58.96%	12.41%
Net Income Growth	42.82%	134.27%	375.41%	-103.30%	-8.94%	-339.46%	-171.82%	-32.55%	213.46%	10.33%	-38.83%
EPS Growth	42.82%	125.19%	249.20%	-7.14%	38.68%	-230.00%	-145.61%	18.22%	160.38%	66.06%	40.85%
Operating Cash Flow Growth	61.44%	39.67%	29.64%	74.40%	-121.81%	-0.37%	-36.33%	-158.29%	39.78%	37.35%	33.69%
Free Cash Flow Firm Growth	-175.17%	-158.22%	-275.01%	-51.06%	-53.33%	-284.89%	-22.88%	64.66%	105.47%	87.63%	103.89%
Invested Capital Growth	36.79%	18.84%	66.05%	77.51%	87.38%	90.14%	79.86%	64.15%	82.53%	56.70%	-261.48%
Revenue Q/Q Growth	-46.36%	149.84%	183.77%	-98.85%	10.76%	-95.45%	-37.93%	-27.78%	263,007.69%	-68.31%	-100.00%
EBITDA Q/Q Growth	-23.05%	159.02%	362.04%	-148.15%	-7.22%	-27.63%	-3.33%	7.23%	218.42%	-172.55%	-77.92%
EBIT Q/Q Growth	-14.67%	141.87%	463.52%	-152.31%	-5.90%	-26.59%	-3.11%	7.37%	212.72%	-177.69%	-74.02%
NOPAT Q/Q Growth	-20.44%	59.83%	676.69%	-161.68%	-16.79%	11.00%	1.06%	5.53%	186.46%	-150.79%	-111.14%
Net Income Q/Q Growth	-101.62%	152.72%	281.33%	-150.15%	-8.04%	-15.89%	-14.37%	7.43%	192.47%	-191.60%	-77.06%
EPS Q/Q Growth	-101.62%	140.09%	174.71%	-148.18%	-15.56%	15.00%	3.62%	13.62%	185.33%	-147.77%	-68.00%
Operating Cash Flow Q/Q Growth	63.53%	-125.35%	21.66%	60.24%	-216.02%	-1.98%	-6.40%	24.67%	26.33%	-6.11%	-12.61%
Free Cash Flow Firm Q/Q Growth	-18.24%	58.49%	-35.76%	-126.72%	-20.01%	-4.19%	56.66%	34.79%	118.56%	-335.87%	113.62%
Invested Capital Q/Q Growth	-7.23%	-4.86%	64.58%	43.53%	39.85%	18.02%	27.66%	-0.49%	70.69%	-103.22%	-503.84%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
EBITDA Margin	-176.37%	41.66%	67.84%	-2,829.69%	-2,739.03%	-76,906.90%	-128,088.89%	-164,523.08%	74.05%	-169.55%	0.00%
Operating Margin	-211.57%	-23.81%	48.39%	-3,693.58%	-3,894.36%	-76,248.28%	-121,538.89%	-158,976.92%	36.57%	-83.73%	0.00%
EBIT Margin	-196.36%	32.90%	65.34%	-2,961.28%	-2,831.35%	-78,851.72%	-131,044.44%	-168,069.23%	72.00%	-176.54%	0.00%
Profit (Net Income) Margin	-231.44%	48.84%	65.63%	-2,851.56%	-2,781.35%	-70,913.79%	-130,666.67%	-167,476.92%	58.86%	-170.15%	0.00%
Tax Burden Percent	121.17%	100.00%	99.43%	100.00%	98.95%	100.04%	100.11%	99.99%	102.29%	99.98%	100.00%
Interest Burden Percent	97.27%	148.43%	101.02%	96.29%	99.28%	89.89%	99.61%	99.66%	79.92%	96.40%	98.07%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-154.66%	-71.52%	31.21%	18.36%	19.05%	-50.81%	-143.89%	-205.16%	-61.52%	-69.52%	-132.91%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-48.09%	9.73%	32.96%	-1,400.37%	-1,313.45%	-26,087.85%	-1,202.99%	-950.79%	16.97%	-59.31%	0.00%
Return on Assets (ROA)	-56.68%	14.44%	33.11%	-1,348.49%	-1,290.26%	-23,461.61%	-1,199.52%	-947.44%	13.87%	-57.17%	0.00%
Return on Common Equity (ROCE)	-154.66%	-71.52%	31.21%	18.36%	19.05%	-50.81%	-143.89%	-205.16%	-61.52%	-69.52%	-132.91%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-74.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-10	-4.19	24	-15	-17	-15	-15	-14	13	-6.35	-13
NOPAT Margin	-148.10%	-23.81%	48.39%	-2,585.50%	-2,726.05%	-53,373.79%	-85,077.22%	-111,283.85%	36.57%	-58.61%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.25%	10.00%	7.81%	-1.69%	-0.44%	-5.84%	-11.50%	-14.16%	9.54%	-17.68%	-36.43%
Return On Investment Capital (ROIC_SIMPLE)	-25.25%	-7.02%	24.84%	-17.09%	-22.10%	-21.60%	-27.15%	-37.09%	10.91%	-6.45%	-19.81%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	121.33%	47.93%	17.09%	1,522.05%	1,501.10%	29,493.10%	50,705.56%	56,369.23%	21.14%	62.77%	0.00%
R&D to Revenue	190.24%	75.88%	34.52%	2,271.53%	2,493.26%	46,855.17%	70,933.33%	102,707.69%	42.29%	120.96%	0.00%
Operating Expenses to Revenue	311.44%	123.81%	51.99%	3,793.58%	3,964.73%	76,379.31%	121,777.78%	159,053.85%	64.70%	183.70%	0.00%
Earnings before Interest and Taxes (EBIT)	-14	5.79	33	-17	-18	-23	-24	-22	25	-19	-33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-12	7.33	34	-16	-17	-22	-23	-21	25	-18	-33
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.30	2.52	0.90	1.00	0.52	1.01	1.37	3.91	0.60	1.79	4.48
Price to Tangible Book Value (P/TBV)	2.35	2.55	0.91	1.01	0.52	1.03	1.39	4.16	0.61	1.81	4.59
Price to Revenue (P/Rev)	0.89	1.63	0.77	0.86	0.43	0.98	36.93	93.22	1.61	3.02	4.50
Price to Earnings (P/E)	0.00	0.00	3.97	7.52	4.08	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	25.18%	13.30%	24.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	4.71	59.92	0.00	1.25	3.04
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.19	0.60	0.30	0.34	0.40	0.45	0.66	1.35	0.24	0.29	0.50
Long-Term Debt to Equity	0.00	0.00	0.00	0.34	0.40	0.45	0.66	1.35	0.24	0.29	0.50
Financial Leverage	-3.48	-3.30	-2.03	-1.93	-2.14	-2.01	-1.31	-1.27	-1.08	-1.09	-1.33
Leverage Ratio	5.02	5.03	3.20	3.38	3.94	3.57	2.53	3.03	1.96	2.14	2.96
Compound Leverage Factor	4.88	7.47	3.23	3.26	3.91	3.21	2.52	3.02	1.56	2.06	2.90
Debt to Total Capital	54.30%	37.64%	23.14%	25.56%	28.36%	31.16%	39.63%	57.36%	19.54%	22.76%	33.11%
Short-Term Debt to Total Capital	54.30%	37.64%	23.14%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	25.56%	28.36%	31.16%	39.63%	57.36%	19.54%	22.76%	33.11%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	45.70%	62.36%	76.86%	74.44%	71.64%	68.84%	60.37%	42.64%	80.46%	77.24%	66.89%
Debt to EBITDA	-0.64	-1.41	1.20	1.79	3.02	-1.00	-0.28	-0.27	-0.54	-0.60	-0.48
Net Debt to EBITDA	2.79	7.46	-5.58	-6.59	-9.08	2.61	0.51	0.28	2.27	2.12	1.40
Long-Term Debt to EBITDA	0.00	0.00	0.00	1.79	3.02	-1.00	-0.28	-0.27	-0.54	-0.60	-0.48
Debt to NOPAT	-0.73	-0.93	-3.08	-1.37	-0.85	-0.72	-0.35	-0.36	-0.61	-0.82	-0.88
Net Debt to NOPAT	3.18	4.90	14.30	5.07	2.57	1.88	0.64	0.37	2.57	2.90	2.59
Long-Term Debt to NOPAT	0.00	0.00	0.00	-1.37	-0.85	-0.72	-0.35	-0.36	-0.61	-0.82	-0.88
Altman Z-Score	-3.44	-2.02	-1.36	-2.91	-3.96	-4.78	-6.47	-7.99	-2.65	-3.40	-4.64
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.73	4.82	4.37	9.22	6.34	6.62	5.18	3.45	13.32	14.02	12.82
Quick Ratio	2.59	4.49	4.13	8.46	5.78	6.23	4.59	2.99	12.97	13.56	12.26
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-55	-23	-31	-70	-84	-87	-38	-25	4.59	-11	1.47
Operating Cash Flow to CapEx	0.00%	-73,003.85%	-53,103.57%	-15,158.97%	-19,260.82%	-29,768.75%	0.00%	0.00%	0.00%	-85,264.29%	0.00%
Free Cash Flow to Firm to Interest Expense	-94.50	-39.56	-55.06	-273.05	-214.01	-246.92	-105.83	-68.25	13.18	-34.77	4.91
Operating Cash Flow to Interest Expense	-14.55	-33.07	-26.55	-23.09	-47.66	-53.82	-56.62	-42.18	-32.33	-38.38	-44.81
Operating Cash Flow Less CapEx to Interest Expense	-14.44	-33.11	-26.60	-23.25	-47.91	-54.00	-56.61	-42.14	-32.26	-38.43	-44.80
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.24	0.30	0.50	0.47	0.46	0.33	0.01	0.01	0.24	0.34	0.38
Accounts Receivable Turnover	60.12	106.15	204.05	40.61	121.59	259.60	0.00	7.27	0.00	22.51	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	5.37	4.82	7.80	12.21	14.57	12.78	0.38	0.25	15.18	23.11	27.14
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	6.07	3.44	1.79	8.99	3.00	1.41	0.00	50.20	0.00	16.21	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	6.07	3.44	1.79	8.99	3.00	1.41	0.00	50.20	0.00	16.21	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-76	-80	-28	-16	-9.60	-7.87	-5.69	-5.72	-1.68	-3.41	-21
Invested Capital Turnover	-0.50	-0.65	-1.57	-1.73	-1.60	-1.17	-0.07	-0.06	-6.08	-7.99	-3.43
Increase / (Decrease) in Invested Capital	44	19	55	55	66	72	23	10	7.92	4.46	-15
Enterprise Value (EV)	-54	-25	-37	-17	-38	-8.09	5.94	42	-39	56	137
Market Capitalization	43	94	67	65	29	50	47	65	55	136	203
Book Value per Share	$0.16	$5.38	$10.79	$8.97	$7.35	$4.71	$3.07	$1.41	$6.96	$3.08	$1.76
Tangible Book Value per Share	$0.16	$5.32	$10.73	$8.91	$7.27	$4.65	$3.02	$1.33	$6.87	$3.03	$1.71
Total Capital	41	60	97	87	79	72	56	39	115	99	68
Total Debt	22	22	22	22	22	22	22	22	22	22	22
Total Long-Term Debt	0.00	0.00	0.00	22	22	22	22	22	22	22	22
Net Debt	-97	-119	-104	-82	-67	-58	-41	-23	-94	-80	-66
Capital Expenditures (CapEx)	-0.06	0.03	0.03	0.04	0.10	0.06	-0.00	-0.02	-0.03	0.01	-0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.89	12	10	-2.66	-6.30	-7.51	-5.55	-8.16	-5.76	-0.25	-3.14
Debt-free Net Working Capital (DFNWC)	109	150	134	99	80	70	57	37	110	101	84
Net Working Capital (NWC)	86	127	111	99	80	70	57	37	110	101	84
Net Nonoperating Expense (NNE)	5.87	-13	-8.60	1.53	0.35	5.09	8.21	7.31	-7.63	12	19
Net Nonoperating Obligations (NNO)	-95	-117	-103	-81	-66	-57	-40	-22	-94	-80	-66
Total Depreciation and Amortization (D&A)	1.41	1.54	1.24	0.76	0.59	0.56	0.53	0.46	0.70	0.76	0.60
Debt-free, Cash-free Net Working Capital to Revenue	-16.20%	21.18%	11.41%	-3.54%	-9.18%	-14.69%	-440.21%	-1,169.20%	-16.80%	-0.55%	-6.97%
Debt-free Net Working Capital to Revenue	223.25%	260.64%	152.41%	131.22%	116.47%	136.31%	4,495.72%	5,259.17%	320.53%	223.94%	187.35%
Net Working Capital to Revenue	177.26%	221.60%	126.74%	131.22%	116.47%	136.31%	4,495.72%	5,259.17%	320.53%	223.94%	187.35%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($127.20)	$1.70	$4.70	($2.25)	($2.60)	($2.21)	($2.13)	($1.84)	$1.57	($0.75)	($1.26)
Adjusted Weighted Average Basic Shares Outstanding	128.05K	5.06M	6.97M	7.29M	6.83M	9.29M	11.05M	11.82M	12.83M	24.63M	25.86M
Adjusted Diluted Earnings per Share	($127.20)	$1.70	$4.67	($2.25)	($2.60)	($2.21)	($2.13)	($1.84)	$1.57	($0.75)	($1.26)
Adjusted Weighted Average Diluted Shares Outstanding	128.05K	5.06M	7.01M	7.29M	6.88M	9.29M	11.05M	11.82M	12.83M	24.63M	25.86M
Adjusted Basic & Diluted Earnings per Share	($127.20)	$0.00	$0.00	$0.00	($2.60)	$0.00	$0.00	$0.00	$1.57	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	230.54K	6.93M	7.23M	7.67M	10.48M	11.09M	11.79M	13.26M	24.73M	25.80M	27.60M
Normalized Net Operating Profit after Tax (NOPAT)	-10	-2.93	17	-15	-17	-15	-15	-14	8.76	-6.36	-13
Normalized NOPAT Margin	-148.10%	-16.67%	34.14%	-2,585.50%	-2,726.05%	-53,352.07%	-84,980.00%	-111,300.00%	25.60%	-58.64%	0.00%
Pre Tax Income Margin	-191.01%	48.84%	66.01%	-2,851.56%	-2,810.97%	-70,882.76%	-130,527.78%	-167,500.00%	57.55%	-170.19%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-23.87	10.08	58.22	-66.63	-46.08	-64.60	-65.89	-60.36	70.77	-61.52	-110.99
NOPAT to Interest Expense	-18.00	-7.29	43.12	-58.17	-44.37	-43.72	-42.78	-39.96	35.94	-20.43	-44.71
EBIT Less CapEx to Interest Expense	-23.76	10.03	58.17	-66.78	-46.33	-64.78	-65.88	-60.31	70.84	-61.57	-110.98
NOPAT Less CapEx to Interest Expense	-17.89	-7.34	43.07	-58.33	-44.62	-43.91	-42.77	-39.92	36.01	-20.47	-44.71
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Precision BioSciences (NASDAQ:DTIL) continues to face a challenging operating environment. Revenue has been highly volatile, rising to $49.9 million in Q2 2024 and $34.2 million in Q4 2025 before falling to $10.8 million in Q1 2026 and zero in Q2 2026. The lack of consistent revenue makes it difficult to evaluate the company on a recurring commercial-growth basis.

Operating expenses have improved modestly. Q2 2026 operating expenses were $19.2 million, down from $22.1 million in Q4 2024, with research and development spending declining to $12.4 million from $15.9 million over the same period. However, the company still reported a $19.2 million operating loss and a $32.7 million net loss in Q2 2026, including $14.1 million of net other expense.

Liquidity remains a key support for the business, but cash is declining. Cash and equivalents fell to $86.1 million at June 30, 2026, from $99.4 million at March 31 and $123.6 million at June 30, 2024. Based on Q2 operating cash outflow of $13.4 million, the company had roughly six to seven quarters of cash coverage before considering changes in spending, financing, investments or potential revenue. This is only an estimate and should not be treated as formal guidance.

Strong near-term liquidity: Cash, short-term investments and long-term investments totaled approximately $88.7 million at the end of Q2 2026, compared with $7.1 million of current liabilities.
Lower operating cost base: Quarterly SG&A and R&D expenses have generally declined from late 2024 levels, indicating some progress in controlling spending.
Limited capital expenditure requirements: Q2 2026 investing cash flow was essentially neutral, suggesting the company is not currently consuming substantial cash on property and equipment expansion.
Revenue remains unpredictable: The company has recorded occasional large revenue quarters, but revenue fell from $34.2 million in Q4 2025 to zero in Q2 2026. Investors should not assume prior licensing or collaboration-related revenue will recur.
Restated historical figures require caution: Several 2024 and 2025 income statement and cash flow figures were marked as restated, which may affect comparisons with previously published results.
Persistent operating losses: DTIL has posted operating losses in most of the reported quarters, including a $19.2 million loss in Q2 2026 despite having no revenue.
Accelerating cash burn: Operating cash outflow increased from $5.9 million in Q3 2024 to $13.4 million in Q2 2026, while net cash declined by $13.4 million during the latest quarter.
Large accumulated deficit: Retained earnings were negative $579.3 million at June 30, 2026, reflecting substantial cumulative losses and limited financial self-sufficiency.
Balance-sheet deterioration: Total assets fell from $143.9 million at the end of Q1 2026 to $125.9 million in Q2, while total liabilities rose from $67.8 million to $80.6 million. Shareholders’ equity declined to $45.3 million from $76.1 million.
Potential need for additional financing: DTIL has repeatedly raised capital through common-equity issuances, including $77.5 million in Q4 2025. Continued losses and cash burn could require additional equity financing, creating dilution risk for existing shareholders.

10/10/26 04:08 AM ETAI Generated. May Contain Errors.

Precision BioSciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Precision BioSciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Precision BioSciences' net income appears to be on an upward trend, with a most recent value of -$45.72 million in 2025, rising from -$98.55 million in 2019. The previous period was $7.17 million in 2024. Find out what analysts predict for Precision BioSciences in the coming months.

Precision BioSciences' total operating income in 2025 was -$52.15 million, based on the following breakdown:

Total Gross Profit: $34.26 million
Total Operating Expenses: $86.87 million

Over the last 6 years, Precision BioSciences' total revenue changed from $22.24 million in 2019 to $34.26 million in 2025, a change of 54.1%.

In the past 11 quarters, Precision BioSciences' cash and equivalents has ranged from $44.87 million in Q3 2025 to $137.77 million in Q1 2024, and is currently $86.08 million as of their latest financial filing in Q2 2026.

Precision BioSciences had total debt of $22.40 million at the end of 2025, a 0.4% increase from 2024, and none in 2019.

Over the last 6 years, Precision BioSciences' book value per share changed from 2.72 in 2019 to 6.96 in 2025, a change of 155.5%.

Related Companies

Financial statements for NASDAQ:DTIL last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precision BioSciences (DTIL) Financials

Financials Breakdown Chart

Key Financial Trends

Precision BioSciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precision BioSciences (DTIL) Financials

Annual Income Statements for Precision BioSciences

Quarterly Income Statements for Precision BioSciences

Annual Cash Flow Statements for Precision BioSciences

Quarterly Cash Flow Statements for Precision BioSciences

Annual Balance Sheets for Precision BioSciences

Quarterly Balance Sheets for Precision BioSciences

Annual Metrics And Ratios for Precision BioSciences

Quarterly Metrics And Ratios for Precision BioSciences

Financials Breakdown Chart

Key Financial Trends

Precision BioSciences Financials - Frequently Asked Questions

When does Precision BioSciences' financial year end?

How has Precision BioSciences' net income changed over the last 6 years?

What is Precision BioSciences' operating income?

How has Precision BioSciences' revenue changed over the last 6 years?

How much cash does Precision BioSciences have?

How much debt does Precision BioSciences have?

How has Precision BioSciences' book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools